During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implications?
Ghobrial begins by outlining the initial results of the PROMISE study, including the benefits of using mass spectrometry for identifying MGUS. Finally, Ghobrial discusses the overall survival and comorbidities that are associated with monoclonal gammopathies.
15 окт 2024